Klaus Dembowsky
Directeur Général chez amcure GmbH
Profil
Klaus Dembowsky is currently the Chief Executive Officer at amcure GmbH.
Previously, he held the position of Chief Executive Officer at Speedel Pharma AG.
He also served as the Chief Medical Officer & Medical Director at Spexis Ltd.
and as a Manager at Bayer AG.
Additionally, he was the Vice President-Drug Discovery at Ingenium Pharmaceuticals GmbH.
Dr. Dembowsky earned a doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1982.
Postes actifs de Klaus Dembowsky
| Sociétés | Poste | Début |
|---|---|---|
amcure GmbH
 amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Directeur Général | - |
Anciens postes connus de Klaus Dembowsky
| Sociétés | Poste | Fin |
|---|---|---|
| SPEXIS AG | Directeur Technique/Scientifique/R&D | - |
| BAYER AG | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - |
Speedel Pharma AG
 Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Directeur Général | - |
Formation de Klaus Dembowsky
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BAYER AG | Health Technology |
| SPEXIS AG | Health Technology |
| Entreprise privées | 3 |
|---|---|
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | Health Technology |
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
amcure GmbH
amcure GmbH BiotechnologyHealth Technology amcure GmbH develops active ingredients for the treatment of angiogenesis-related diseases. It offers a peptide based substance, that targets the tumor specific co-receptors. The company was founded by Matthias Klaften and Alexandra Matzke on December 14, 2011 and is headquartered in Eggenstein-Leopoldshafen, Germany. | Health Technology |